1. Home
  2. USAU vs MGNX Comparison

USAU vs MGNX Comparison

Compare USAU & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. Gold Corp.

USAU

U.S. Gold Corp.

SELL

Current Price

$11.43

Market Cap

242.1M

ML Signal

SELL

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$2.39

Market Cap

262.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USAU
MGNX
Founded
2014
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
242.1M
262.4M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
USAU
MGNX
Price
$11.43
$2.39
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
★ $26.50
$8.00
AVG Volume (30 Days)
150.9K
★ 892.6K
Earning Date
12-09-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 36.11
N/A
EPS
N/A
★ N/A
Revenue
$17,402,000.00
★ $149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$10.44
$1.29
52 Week High
$23.72
$5.08

Technical Indicators

Market Signals
Indicator
USAU
MGNX
Relative Strength Index (RSI) 33.77 31.00
Support Level N/A $1.63
Resistance Level $16.45 $3.46
Average True Range (ATR) 0.63 0.31
MACD -0.01 -0.10
Stochastic Oscillator 27.29 24.04

Price Performance

Historical Comparison
USAU
MGNX

About USAU U.S. Gold Corp.

U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: